Daiichi Sankyo is participating in Access Accelerated, which was established in 2017 by more than 20 pharmaceutical companies from Japan, the United States, and Europe in partnership with the World Bank and the Union for International Cancer Control, among others, with the purpose of improving prevention, diagnosis, treatment, and other aspects of NCDs^* in low-income and lower-middle income countries.

Access Accelerated is working to improve access to healthcare in target countries to achieve one of the targets of Goal 3 of the SDGs: “By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.”

*Non-Communicable Diseases  such as cancer, cardiovascular disease, chronic respiratory disease, and diabetes.

Please watch the video message from our CEO at the time, which was published when we began participating in this initiative.

Access Accelerated’s activities are summarized in annual reports. The Access Accelerated 2021 Measurement Framework Report, which summarized the initiative’s activities for the year was published in May 2022.

For more information on Access Accelerated’s activities, please visit the following website:

• Access Accelerated
• Year One Report
• Year Two Report
• Year Three Report
• Access Accelerated 2021 Measurement Framework Report